Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
5.02
-0.01 (-0.20%)
Jun 6, 2025, 4:08 PM HKT
43.43%
Market Cap 17.62B
Revenue (ttm) 5.66B
Net Income (ttm) 695.08M
Shares Out n/a
EPS (ttm) 0.47
PE Ratio 25.35
Forward PE n/a
Dividend 0.27 (5.41%)
Ex-Dividend Date May 26, 2025
Volume 1,563,000
Average Volume 2,225,900
Open 5.11
Previous Close 5.03
Day's Range 4.94 - 5.11
52-Week Range 3.02 - 5.92
Beta 0.37
RSI 60.18
Earnings Date Aug 29, 2025

About HKG:9989

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates through four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. The company’s pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium ... [Read more]

Sector Healthcare
Founded 1998
Employees 1,926
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9989
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.